EOS imaging Leadership Transition to Strengthen U.S. Strategy

PARIS–(BUSINESS WIRE)–Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of orthopedic medical imaging 2D / 3D, announces the change of its leadership effective January 1, 2019.

The Board of Directors, in agreement with Marie Meynadier, Chief Executive Officer of EOS imaging, has decided to change the leadership of the company to strengthen the company’s presence in the United States, its largest market, and expand its shareholder base.

The Board has unanimously appointed Mike Lobinsky, who joined the company in August 2017 as President North America, to the position of Chief Executive Officer effective January 1, 2019. Marie Meynadier will continue as Chief Executive Officer of EOS Imaging until December 31, 2018 and thereafter retains a position on the Board of Directors. Also being considered is Mike Lobinsky’s nomination to Director of EOS imaging at a subsequent Shareholder General Meeting.

Mike Lobinsky has over twenty years’ experience in the medtech industry with senior management roles in sales, marketing, operations and business development in the fields of Orthopedic Robotics, Navigation, Imaging and Implants. He has held leadership positions at Smith and Nephew, Brainlab, Blue Belt Technologies, Stryker and most recently contributed to the acquisition of Blue Belt by S&N prior to joining EOS in 2018.

Marie Meynadier, Chief Executive Officer of EOS Imaging, said, “I have enjoyed working with Mike for over a year. His leadership and knowledge of the industry, combined with his fine understanding of corporate culture, are excellent assets for EOS imaging and I have complete confidence in his ability to continue and accelerate the development of the company. Our North American market is considerable, and Mike will be able to develop it without denying our European roots, relying on the talented management team present in Paris, particularly Eric Maulavé, Chief Operating Officer, to continue to drive global growth. It was an honor and a great pleasure to serve the company and to develop it since its foundation. I am most grateful to the men and women within our staff, to our Directors, shareholders and clinical partners, who contributed to this development over these last years. Our teams can be proud of the work accomplished, and I have full confidence that they will continue to build our success under Mike’s leadership.”

Gérard Hascoet, Chairman of the Board of Directors of EOS Imaging, commented: “Marie’s vision, her energy and her remarkable managerial talent have brought EOS imaging to a stage of excellence and a unique international reputation. Marie has given the company access today to an acceleration opportunity in the United States, which is a new step. She has managed to attract a management team capable of taking up this new challenge and ensure a successful succession. It is rare to be able to apprehend the future in such optimism.”

Mike Lobinsky, President North America, EOS Imaging, added: “I am very grateful to Marie and the Board members for their trust and pleased to accept the CEO position. Few companies have accomplished what EOS has and these achievements have established a strong foundation for further development. The potential of our entire solution is outstanding, and I am confident in our ability to translate this into growth and value in the short, medium, and long terms.”

Valérie Worrall also joins the company as Chief Financial Officer. Valérie Worrall has more than twenty years of experience in leadership finance roles and as the CFO within business units in the healthcare industry. She has held positions in South East Asia, the United States, Switzerland, the UK, and France. She most recently was CFO of Balt, a medical device company.

ABOUT EOS IMAGING

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 33 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 280 installed EOS® platforms representing more than one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.